Financing ·
Integra LifeSciences Holdings Corp filed an updated investor presentation on September 8, 2026, intended for use with…
IARTIntegra Lifesciences Holdings Corp
Integra LifeSciences Holdings Corp filed an updated investor presentation on September 8, 2026, intended for use with prospective lenders as the company plans to refinance its outstanding senior credit facility in 2026. The presentation highlights trailing twelve-month revenue of $1.6 billion and adjusted EBITDA of $337 million, representing a 20.5% margin. Key operational milestones include the Q2 2026 activation of a new Braintree, Massachusetts manufacturing site and an anticipated Q4 2026 relaunch of the SurgiMend product. The company reports net leverage has decreased to 4.1x from 4.5x at year-end 2025, with a target range of 2.5x to 3.5x. Integra LifeSciences Holdings Corp operates in the medical device industry, specializing in neurosurgery and regenerative tissue repair solutions.